- IN₹229.07bn
- IN₹234.65bn
- IN₹53.66bn
Paracetamol maker Granules India posts marginal rise in Q3 profit
Brief: Granules India Dec-Quarter Consol Profit Rises Marginally
Brief: Granules India Receives ANDA Approval For Pantoprazole Sodium Delayed-Release Tablets
Granules India hits highest in over 2 years
Brief: Granules India Says Got Order From GST Authorites Directing Co To Pay Tax, Interest, Penalty Worth 4.3 Million Rupees
Paracetamol maker Granules India's Q2 revenue rises on higher N.America demand
Brief: Granules India Sept-Quarter Consol Profit Falls
Indian paracetamol maker Valiant Laboratories lists at 16% premium
India's Nifty Pharma up 1.3%, set to snap six-session losing streak
Brief: Granules India Received Accreditation Certificate Of Foreign Drug Manufacturer From PMDA
Brief: Granules India Received Approval From Brazilian Health Regulatory Agency (Anvisa)
Granules India slumps on Q1 profit fall
Brief: Granules India Says Q1 Sales And PAT Impacted Severely By Business Interruption Caused By IT Incident
Paracetamol maker Granules India' Q1 profit hurt by cyber attack disruptions
Brief: Granules India June-Quarter Consol Profit Falls
Brief: Granules India Gets US FDA Approval For ANDA Filed For Metoprolol Succinate ER Tablets
Brief: Granules India Says Granules Pharmaceuticals Completes USFDA Postmarketing Adverse Drug Experience Inspection With 0 Observations
Brief: Granules India Announced Approval For The Store Brand OTC Equivalent Of Advil Dual Action Tablets
Gagillapur Facility Received Eir From Us FDA